Overview

PhytoSERM to Prevent Menopause Associated Decline in Brain Metabolism and Cognition

Status:
Not yet recruiting
Trial end date:
2028-02-28
Target enrollment:
Participant gender:
Summary
This is a proof-of-concept phase 2 clinical trial to investigate the safety and effect of the phytoestrogenic supplement PhytoSERM on regional brain metabolism by fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET) in peri- and postmenopausal women. The investigators hypothesize that there will be a significant difference between the PhytoSERM group and placebo group in glucose brain metabolism.
Phase:
Phase 2
Details
Lead Sponsor:
University of Arizona
Collaborator:
National Institute on Aging (NIA)